Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Breast Neoplasms 88Neoplasm Metastasis 4HER2-positive Breast Cancer 4Stomach Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Esophageal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants 1Thyroid Neoplasms 1Thrombocytosis 1Sarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Preference 1Pathologic Complete Response 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Metastatic HER2-positive Breast Cancer With Brain Metastasis 1

Interventions

pembrolizumab 18Trastuzumab 7Docetaxel 7Paclitaxel 6Magnetic Resonance Spectroscopy 5Taxes 4Drug Therapy 4Carboplatin 4Specimen Handling 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Nivolumab 3Injections 3Fluorouracil 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Cisplatin 3Capecitabine 3Biopsy 3poly ICLC 2fludarabine 2durvalumab 2belinostat 2atezolizumab 2Radiotherapy 2Oxaliplatin 2Leucovorin 2Lapatinib 2Irinotecan 2Interleukin-12 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Ado-Trastuzumab Emtansine × Breast × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02318901 2019-10-21

PembroMab

Western Regional Medical Center

Phase 1/2 Terminated
16 enrolled 6 charts
BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡